17,261 trials
Pulmonary Hypertension
Primary: Identify Equivalent Dose of VentaProst Necessary to Achieve a PD Response Comparable to Standard of Care Treatment (Part I) — 17 ng/kg/min
HER2 Positive Breast Cancer
Primary: Confirmed Objective Response Rate (cORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 According to Investigator (INV) Assessment — 51.4…
COVID-19
Primary: Change in Respiratory Failure — 3; 2 Participants
Hand Eczema
Primary: Percentage of Participants With Investigator's Global Assessment-Chronic Hand Eczema Treatment Success (IGA-CHE-TS) at Week 16 — 53.2; 10.9 percentage of participants…
Pruritus
Primary: Change From Baseline in the Worst Itch Numeric Rating Scale (WI-NRS) Score up to Week 6 — -2.20; -1.75 scores on a scale — p=0.4577
Locally Advanced Paraganglioma · Metastatic Adrenal Gland Pheochromocytoma · Metastatic Paraganglioma
Primary: Objective Response Rate — 25 percentage of participants
CMV · CMV Infection · Hematopoietic Cell Transplant
Primary: Clinically Significant CMV Viremia for Hematopoietic Cell Transplantation/HCT Participants in the Interventional Cohort Only — 5; 0; 31; 0 Participants
Mycobacterium Infections, Nontuberculous · Mycobacterium Abscessus Infection · Nontuberculous Mycobacterial Lung Disease
Primary: Percentage of Participants With Clinical Response on NTM Symptom Assessment Scale at Day 84 — 34.1; 20.0 Percentage of participants — p=0.2182
Cervical Cancer
Primary: DLT Evaluation for Safety and Tolerability(Part A) — 0 participants
Advanced Cancer · Cervical Cancer
Primary: Phase 1: Number of Participants Experiencing Dose-limiting Toxicities (DLTs) for Balstilimab — 0; 0; 0; 0 Participants
Advanced Pancreatic Carcinoma · Locally Advanced Pancreatic Carcinoma · Metastatic Pancreatic Carcinoma
Primary: Tumor Response — 5; 3 Participants
Mild Cognitive Impairment
Primary: Correction Rate in Memory Association Recall — .106; .031 units on a scale
Pancreatic Cancer Non-resectable · Pancreatic Cancer Metastatic
Primary: Disease Control Rate (DCR) at 4 Months Using RECIST 1.1 — 2 Participants
Plague, Pneumonic · Plague · Vaccine-Preventable Diseases
Primary: Rates of Reactogenicity and Safety — 16; 67; 57; 0 Participants
Granulosa Cell Ovarian Cancer · Low Grade Serous Ovarian/ Primary Peritoneal Cancer · Endometrioid Endometrial Cancer
Primary: Overall Response Rate — 0; 0; 0; 0 Participants